Indication

As maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Medicine details

Medicine name:
indacaterol/glycopyrronium/mometasone furoate (Enerzair Breezhaler)
SMC ID:
SMC2355
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Respiratory system
Submission type
Abbreviated
Publication due date:
10 May 2021